Blockade of receptors for growth factors: An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 747-753

  Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOXORUBICIN; GROWTH FACTOR RECEPTOR; PACLITAXEL;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; METASTASIS INHIBITION; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0034114769     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Cohen, S., Carpenter, G., and King, L., Jr. Epidermal growth factor receptor-kinase-interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem., 255: 4834-4842, 1980.
2. Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal. J. Biol. Chem., 237: 1555-1562, 1962.
3. Sporn, M. B., and Todaro, G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med., 303: 878-880, 1980.
4. Barnes, D., and Sato, G. Serum-free cell culture: a unifying approach. Cell, 22: 649-655, 1980.
5. Cooper, J. A., and Hunter, T. Similarities and differences between the effect of epidermal growth factor and Rous sarcoma virus. J. Cell Biol., 91: 878-883, 1981.
6. Chinkers, M., and Cohen, S. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature (Lond.), 290: 516-519, 1981.
7. Erickson, E., Shealy, D. J., and Erickson, R. L. Evidence that viral transforming gene products and epidermal growth factor stimulate phosphorylation of the same cellular protein with similar specificity. J. Biol. Chem., 256: 11381-11384, 1981.
8. 1 events and regulation of cell proliferation. Science (Washington DC), 246: 603-608, 1989.
9. Kawamoto, T. K., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA, 80: 1337-1341, 1983.
10. Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med., 1: 511-529, 1983.
11. Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem., 259: 7755-7760, 1984.
12. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., and Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 44: 1002-1007, 1984.
13. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.
14. Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (Lond.), 307: 521-527, 1984.
15. Xu, Y. H., Ishii, S., Clark, A. J., Sullivan, M., Wilson, R. K., Ma, D. P., Roe, B. A., Merlino, G. T., and Pastan, I. Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (Lond.), 309: 806-810, 1984.
16. Lin, C. R., Chen, W. S., Kruiger, W., Stolarsky, L. S., Weber, W., Evans, R. M., Verma, I. M., Gill, G. N., and Rosenfeld, M. G. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (Washington DC), 224: 843-848, 1984.
17. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., and Schlessinger, J. Human epidermal growth factor receptor cRNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-425, 1984.
18. Doolittle, R. F., Hunkapiller, M. W., Hood, L. E., Devare, S. G., Robbins, K. C., Aaronson, S. A., and Antoniades, H. N. Simian sarcoma virus oncogene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science (Washington DC), 221: 275-277, 1983.
19. sis of simian sarcoma virus. Nature (Lond.), 304: 35-39, 1983.
20. Ozanne, B., Richards, C. S., Hendler, F., Burns, D., and Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol., 149: 9-14, 1986.
21. Sobol, R. E., Astarita, R. W., Hofeditz, C., Masui, H., Fairshter, R., Royston, I., and Mendelsohn, J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J. Natl. Cancer Inst., 79: 403-407, 1987.
22. Veale, D., Kerr, N., Gibson, G. H., and Harris, A. L. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res., 49: 1313-1317, 1989.
23. Sainsbury, J. R. C., Malcolm, A. J., Appleton, D. R., Farndon, J. R., and Harris, A. L. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol., 38: 1225-1228, 1985.
24. Gullick, W. J. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int. J. Cancer, 5 (Suppl.): 55-61, 1990.
25. Neal, D. E., Bennett, M. K., Hall, R. R., Marsh, C., Abel, P. D., Sainsbury, J. R. C., and Harris, A. L. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet, 1: 366-368, 1985.
26. Drebin, J. A., Link, V. C., Weinberg, R. A., and Greene, M. I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA, 83: 9129-9133, 1986.
27. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
28. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
29. Divgi, C. R., Welt, S., Kris, M., Real, F. X., Yeh, S. D. J., Gralla, R., Merchant, B., Schweighart, S., Unger, M., Larson, S. M., and Mendelsohn, J. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst., 83: 97-104, 1991.
30. Goldstein, N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
31. 1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res. Treat., 55: 267-283, 1999.
32. Markowitz, S. D., Molkentin, K., Gerbic, C., Jackson, J., Stellato, T., and Willson, J. K. V. Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J. Clin. Investig., 86: 356-362, 1990.
33. Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Investig., 95: 1897-1905, 1995.
34. 1 arrest in prostatic cancer cell line DU145. Cancer Res., 56: 3666-3669, 1996.
35. Waterfield, M. D., Mayes, E. L. V., Stroobant, P., Bennett, P. L. P., Young, S., Goodfellow, P. N., Banting, G. S., and Ozanne, B. A monoclonal antibody to the human epidermal growth factor receptor. J. Cell. Biochem., 20: 149-161, 1982.
36. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.
37. Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res., 3: 1943-1948, 1997.
38. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
39. Mandai, M., Adam, L., Mendelsohn, J., and Kumar, R. Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. Oncogene, 17: 999-1007, 1998.
40. Huang, S. M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
41. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res., 5: 875-881, 1999.
42. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
43. Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin. Cancer Res., in press, 2000.
44. Fan, Z., Masui, H., Atlas, I., and Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res., 53: 4322-4328, 1993.
45. Naramura, M., Gillies, S. D., Mendelsohn, J., Reisfeld, R. A., and Mueller, B. A. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother., 37: 343-349, 1993.
46. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
47. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
48. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
49. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
50. Baselga, J., Norton, L., Coplan, K., Shalaby, R., and Mendelsohn, J. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts. Proc. Am. Assoc. Cancer Res., 35: A2262, 1994.
51. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 909-916, 1999.
52. Meikrantz, W., and Schlegel, R. Apoptosis and the cell cycle. J. Cell. Biochem., 58: 160-174, 1995.
53. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
54. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-pi85HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
55. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
56. Baselga, J., Norton, L., Albanell, J., Kim, Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
57. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy tor HER2-overexpressing metastatic breast cancer (HER2 +/MBC) markedly increases anticancer activity: a randomized multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., 17: 98a, 1998.
58. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Anderson, V., Waksal, H., and Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., in press, 2000.
59. Ezekiel, M. P., Robert, F., Meredith, R. F., Spencer, S. A., Newsome, J., Khazaeli, M. B, Peters, G. E, Saleh, M., LoBuglio, A. F., and Waksal, H. Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Clin. Oncol., 17: 395a, 1998.
60. Mendelsohn, J., Shin, D. M., Donato, N., Khuri, F., Radinsky, R., Glisson, B. S., Shin, H. J., Metz, E., Pfister, D., Perez-Soler, R., Lawhorn, K., Matsumoto, T., Gunnett, K., Falcey, J., Waksal, H., and Hong, W. K. A Phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). Proc. Am. Soc. Clin. Oncol., 18: 389a, 1999.
61. Mendelsohn, J., and Fan, Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89: 341-343, 1997.